Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

Sponsor
Eastern Cooperative Oncology Group (Other)
Overall Status
Completed
CT.gov ID
NCT00002520
Collaborator
National Cancer Institute (NCI) (NIH)
434
1
2

Study Details

Study Description

Brief Summary

RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.

PURPOSE: Randomized clinical trial to compare the effectiveness of a physician-initiated stop-smoking program with the usual care for patients receiving treatment for early-stage cancer.

Detailed Description

OBJECTIVES:
  • Compare the efficacy of brief physician-initiated smoking cessation strategies vs usual care in patients with early stage cancer who are undergoing treatment in clinical oncology settings.

  • Compare the sociodemographic, smoking history, and health status correlates of smoking cessation in patients treated with these regimens.

  • Determine the feasibility of conducting a cancer prevention and control study in a cooperative group setting by monitoring adherence to the smoking-cessation strategies.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive usual care (no special intervention).

  • Arm II: Patients receive smoking-cessation therapy based on the 4-step intervention plan in the "Manual for Physicians" published by the National Cancer Institute. The smoking cessation coordinator and physician provide self-quitting advice and support to the patient via counseling, self-help materials, and referral to a smoking cessation counselor at the Cancer Information Service (CIS). Patients receive nicotine replacement, if indicated. Patients who express an interest in more intensive treatment are referred to local American Cancer Society or American Lung Association clinics and/or advised to call the CIS for additional local program referrals.

All patients are followed at 6 and 12 months. Patients who report that they are still smoking and interested in help to quit smoking at the 12-month follow-up interview are encouraged to return to their physicians and contact the CIS for additional help quitting or for a referral to more intensive or specialized treatments in their area.

PROJECTED ACCRUAL: A total of 494 patients will be accrued for this study.

Study Design

Study Type:
Interventional
Actual Enrollment :
434 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Official Title:
Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings
Study Start Date :
Jun 1, 1992
Actual Primary Completion Date :
Feb 1, 2002

Arms and Interventions

Arm Intervention/Treatment
Experimental: Quit Smoking Intervention

Patients received advice and help to quit smoking. The intervention employed physician and patient resources that had already been developed and evaluated or pre-tested, including written materials, prescriptions for nicotine replacement, counseling, and follow-up contact.

Drug: nicotine

Active Comparator: Usual Care

No special intervention after randomization. "Usual care" may or may not include advice or assistance to stop smoking. Physicians were reassured that "usual care" did not preclude quit smoking counseling.

Behavioral: Usual Care

Outcome Measures

Primary Outcome Measures

  1. Rate of Smoking Cessation at 6 months [Assessed at 6 months]

    Proportion of patients who have quit smoking 6 months after the intervention

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 120 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
DISEASE CHARACTERISTICS:
  • One of the following diagnoses:

  • Stage I or II bladder, colorectal, head and neck, lung, or other cancer

  • Stage I-III testicular cancer

  • Stage I-IV breast cancer, prostate cancer, or lymphoma

  • Must have smoked 1 or more cigarettes within the past month or define self as a smoker

  • Hormone receptor status:

  • Not specified

PATIENT CHARACTERISTICS:
Age:
  • 19 and over
Sex:
  • Not specified
Menopausal status:
  • Not specified
Performance status:
  • ECOG 0-1
Life expectancy:
  • Not specified
Hematopoietic:
  • Not specified
Hepatic:
  • Not specified
Renal:
  • Not specified
Cardiovascular:
  • No history of recent heart attack
Other:
  • Not pregnant

  • No other imminent medical needs requiring referral to a more intensive smoking cessation regimen

PRIOR CONCURRENT THERAPY:
Biologic therapy:
  • Not specified
Chemotherapy:
  • Not specified
Endocrine therapy:
  • Not specified
Radiotherapy:
  • Not specified
Surgery:
  • Not specified
Other:
  • No prior participation in the pilot phase study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fox Chase Cancer Center Philadelphia Pennsylvania United States 19111

Sponsors and Collaborators

  • Eastern Cooperative Oncology Group
  • National Cancer Institute (NCI)

Investigators

  • Study Chair: Paul F. Engstrom, MD, Fox Chase Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT00002520
Other Study ID Numbers:
  • CDR0000078281
  • U10CA021115
  • E-1Y92
  • NCI-P93-0042
First Posted:
Aug 11, 2003
Last Update Posted:
Oct 7, 2015
Last Verified:
Oct 1, 2015
Keywords provided by Eastern Cooperative Oncology Group
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 7, 2015